Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 09 Mar 2019
The need for postoperative morphine consumption was not reduced even with the concurrent use of low-dose S-ketamine in patients who were undergoing major open gynaecological surgeries using remifentanil–propofol target-controlled infusion (TCI), a local study finds.

Product Highlight - Abstral

01 May 2018
ABSTRAL - Fentanyl citrate 100 mcg, 200 mcg and 400 mcg SL tab - A. Menarini

Innovative

• The first sublingual formulation of fentanyl citrate approved for the treatment of Breakthrough Cancer Pain
Rapid onset
• Quick dissolution allows for rapid transmucosal absorption of fentanyl
Treatment optimisation
• Can be titrated within the recommended dosing regimen to meet the
analgesic requirements of individual patients
Designed for convenient administration
• Non-invasive
• Easy to use

Reference: Abstral Package insert_230217

Further information is available in section 4j, New In This Issue and mims.com.
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Pearl Toh, 09 Mar 2019
The need for postoperative morphine consumption was not reduced even with the concurrent use of low-dose S-ketamine in patients who were undergoing major open gynaecological surgeries using remifentanil–propofol target-controlled infusion (TCI), a local study finds.